Tickers

1. Composite Trajectory Verdict

The income statement, cash flow statement, and balance sheet carry roughly equal weight for OPCH given its capital-intensive infusion services model, significant debt financing, and aggressive share repurchase program that directly alters equity structure.

Composite Trajectory: Mixed

The annual income statement shows revenue growth (+13%) but margin compression (gross margin -100bps to 19.3%, operating margin -40bps to 6.0%) and declining net income (-2.0% to $207.6M). Quarterly trends show improvement: Q2 2026 net income rose 6.7% to $53.9M with operating margin expanding 10bps to 5.9%, though gross margin remains pressured (-50bps YoY). Cash flow deteriorated annually (operating CF -20% to $258M) due to working capital builds, but YTD Q2 2026 operating CF more than doubled to $171M as inventory normalized. The balance sheet reflects deliberate leveraging via buybacks (equity -5.5% annually to $1.33B, debt/equity up to 0.87x from 0.79x) while expanding revolver capacity to $850M ($846M available). These opposing forces — operational margin pressure offset by per-share earnings growth from buybacks, and annual cash flow weakness offset by recent working capital improvement — produce a mixed trajectory.

2. Red Flags

• Gross margin compression persisted across periods: FY2025 19.3% vs FY2024 20.3% (-100bps); Q2 2026 18.5% vs Q2 2025 19.0% (-50bps) despite revenue growth (10-K FY2025, 10-Q Q2 2026).
• Net income declined annually: $207.6M vs $211.8M (-2.0%) even as revenue grew 13% (10-K FY2025).
• Operating cash flow fell 20% annually to $258M from $323M, driven by $81M inventory increase and $55M AR increase (10-K FY2025).
• Share repurchases reduced equity aggressively: treasury stock rose from $508M to $818M (FY2025) and $987M (Q2 2026); total equity fell 5.5% YoY to $1.33B (10-K FY2025, 10-Q Q2 2026).
• Leverage increased: total debt/equity rose to 0.87x (FY2025) from 0.79x (FY2024) as debt grew 4.5% to $1.16B while equity fell (10-K FY2025).
• Effective tax rate climbed: 26.6% vs 25.3% annually; 27.1% vs 26.6% in Q2 (10-K FY2025, 10-Q Q2 2026).
• Other, net swung to -$7.9M from +$4.8M annually due to $4.7M debt extinguishment loss and unclaimed property accruals (10-K FY2025).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual results show top-line growth (revenue +13% to $5.65B) but margin erosion: gross margin fell 100bps to 19.3%, operating margin fell 40bps to 6.0%, and net income declined 2.0% to $207.6M (10-K FY2025). Quarterly trends diverge: Q2 2026 revenue grew 1.9% to $1.44B, operating margin expanded 10bps to 5.9% on 3.2% lower SG&A, and net income rose 6.7% to $53.9M, though gross margin remained 50bps below prior year at 18.5% (10-Q Q2 2026). YTD Q2 2026 net income grew 2.0% to $99.3M with flat SG&A but operating margin compressed 30bps to 5.6% (10-Q Q2 2026). Diluted EPS grew in all comparable periods (FY: $1.27 vs $1.23; Q2: $0.35 vs $0.31; YTD: $0.64 vs $0.59) primarily due to 5-6% share count reduction from buybacks (10-K FY2025, 10-Q Q2 2026).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow declined 20% to $258M from $323M, pressured by strategic inventory purchases (+$81M outflow) and AR growth (+$55M outflow) (10-K FY2025). Investing cash flow increased to -$161M from -$36M due to the $117M Intramed Plus acquisition (10-K FY2025). Financing cash flow reached -$277M vs -$218M, driven by $310M share repurchases vs $253M prior year (10-K FY2025). Conversely, YTD Q2 2026 operating cash flow more than doubled to $171M from $83M as inventory decreased $72M (vs $13M increase prior year) (10-Q Q2 2026). Investing cash flow improved to -$21M (mainly capex) from -$136M (acquisition-heavy) (10-Q Q2 2026). Financing cash flow remained negative at -$189M vs -$161M on higher repurchases ($168M vs $150M) (10-Q Q2 2026).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Annual balance sheet shows deliberate capital restructuring: cash fell 44% to $233M, inventory rose 21% to $471M, and AR rose 16% to $474M (10-K FY2025). Total debt increased 4.5% to $1.16B while equity declined 5.5% to $1.33B, raising debt/equity to 0.87x from 0.79x (10-K FY2025). Revolver capacity was $400M with $396M available. By Q2 2026, inventory normalized (-15% to $400M), cash declined further to $194M, but revolver capacity expanded to $850M with $846M available, enhancing liquidity headroom (10-Q Q2 2026). Equity continued declining to $1.26B (-5% from YE2025) as treasury stock reached $987M; shares outstanding fell to 149.8M from 156.9M (10-Q Q2 2026). Goodwill stable at $1.61B post-Intramed integration.

6. Data Gaps

• Standalone Q3 2025, Q4 2025, and Q1 2026 quarterly income statements and cash flows (only Q2 2026 and YTD provided in 10-Qs).
• Free cash flow (operating CF less capex) not explicitly reported; capex is $41.3M annually and $20.1M YTD Q2 2026 but quarterly capex not isolated.
• Full-year 2026 guidance beyond CID gross profit impact estimate (~$55M) and leverage targets.
• Detailed therapy-level revenue breakdown (acute vs chronic sub-categories) beyond high-level commentary.
• Debt maturity profile beyond the scheduled principal payments shown through 2032.